(24/7 MARKET NEWS) – UNITY Biotechnology, Inc. [Nasdaq: UBX] announced, this morning, that the key safety and efficacy endpoints were met at 24 weeks in the Phase 2 BEHOLD study of UBX1325 in patients with diabetic macular edema (DME). The Company intends to initiate a pivotal study in DME in the second half of 2023.
it’s currently at $3.16, 30 cents higher (+10.49%), on over 2.7 million premarket shares traded.
Its premarket high this morning is $3.81. its 52-week range is $2.46 to $36.40. its next key inflection points are $3.81, $3.95 and $4.30.
24/7 MARKET NEWS, INC Disclaimer
24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.